|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FCER1G |
Gene summary for FCER1G |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FCER1G | Gene ID | 2207 |
| Gene name | Fc fragment of IgE receptor Ig | |
| Gene Alias | FCRG | |
| Cytomap | 1q23.3 | |
| Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | P30273 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2207 | FCER1G | NCCBC11 | Human | Breast | DCIS | 3.67e-03 | 6.06e-01 | 0.1232 |
| 2207 | FCER1G | NCCBC14 | Human | Breast | DCIS | 5.17e-05 | 4.66e-01 | 0.2021 |
| 2207 | FCER1G | NCCBC3 | Human | Breast | DCIS | 2.71e-43 | 9.54e-01 | 0.1198 |
| 2207 | FCER1G | NCCBC5 | Human | Breast | DCIS | 6.39e-17 | 8.40e-01 | 0.2046 |
| 2207 | FCER1G | CA_HPV_2 | Human | Cervix | CC | 5.45e-09 | -3.49e-01 | 0.0391 |
| 2207 | FCER1G | CA_HPV_3 | Human | Cervix | CC | 1.77e-05 | -5.01e-01 | 0.0414 |
| 2207 | FCER1G | CCI_1 | Human | Cervix | CC | 2.86e-12 | -1.17e+00 | 0.528 |
| 2207 | FCER1G | CCI_2 | Human | Cervix | CC | 5.63e-11 | -1.12e+00 | 0.5249 |
| 2207 | FCER1G | CCI_3 | Human | Cervix | CC | 6.33e-15 | -1.14e+00 | 0.516 |
| 2207 | FCER1G | CCII_1 | Human | Cervix | CC | 8.45e-25 | -1.19e+00 | 0.3249 |
| 2207 | FCER1G | Tumor | Human | Cervix | CC | 1.34e-58 | -1.18e+00 | 0.1241 |
| 2207 | FCER1G | sample1 | Human | Cervix | CC | 7.63e-19 | -1.17e+00 | 0.0959 |
| 2207 | FCER1G | sample3 | Human | Cervix | CC | 2.19e-53 | -1.18e+00 | 0.1387 |
| 2207 | FCER1G | H2 | Human | Cervix | HSIL_HPV | 4.80e-49 | -1.12e+00 | 0.0632 |
| 2207 | FCER1G | L1 | Human | Cervix | CC | 9.59e-10 | -8.41e-01 | 0.0802 |
| 2207 | FCER1G | T1 | Human | Cervix | CC | 1.45e-33 | -1.11e+00 | 0.0918 |
| 2207 | FCER1G | T2 | Human | Cervix | CC | 3.91e-12 | -1.19e+00 | 0.0709 |
| 2207 | FCER1G | T3 | Human | Cervix | CC | 4.14e-57 | -1.19e+00 | 0.1389 |
| 2207 | FCER1G | S43 | Human | Liver | Cirrhotic | 7.29e-09 | -4.69e-01 | -0.0187 |
| 2207 | FCER1G | HCC1_Meng | Human | Liver | HCC | 4.03e-19 | -2.93e-01 | 0.0246 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004800222 | Breast | DCIS | antigen processing and presentation of peptide antigen | 20/1390 | 62/18723 | 1.01e-08 | 7.56e-07 | 20 |
| GO:000247822 | Breast | DCIS | antigen processing and presentation of exogenous peptide antigen | 15/1390 | 38/18723 | 3.22e-08 | 2.09e-06 | 15 |
| GO:000249513 | Breast | DCIS | antigen processing and presentation of peptide antigen via MHC class II | 13/1390 | 34/18723 | 4.17e-07 | 1.87e-05 | 13 |
| GO:001988621 | Breast | DCIS | antigen processing and presentation of exogenous peptide antigen via MHC class II | 12/1390 | 30/18723 | 6.56e-07 | 2.79e-05 | 12 |
| GO:001988422 | Breast | DCIS | antigen processing and presentation of exogenous antigen | 15/1390 | 47/18723 | 8.26e-07 | 3.39e-05 | 15 |
| GO:009752921 | Breast | DCIS | myeloid leukocyte migration | 38/1390 | 220/18723 | 8.44e-07 | 3.44e-05 | 38 |
| GO:000250413 | Breast | DCIS | antigen processing and presentation of peptide or polysaccharide antigen via MHC class II | 13/1390 | 36/18723 | 9.02e-07 | 3.65e-05 | 13 |
| GO:003059521 | Breast | DCIS | leukocyte chemotaxis | 39/1390 | 230/18723 | 9.85e-07 | 3.93e-05 | 39 |
| GO:005090021 | Breast | DCIS | leukocyte migration | 54/1390 | 369/18723 | 1.22e-06 | 4.78e-05 | 54 |
| GO:007162121 | Breast | DCIS | granulocyte chemotaxis | 26/1390 | 125/18723 | 1.32e-06 | 5.09e-05 | 26 |
| GO:000181921 | Breast | DCIS | positive regulation of cytokine production | 63/1390 | 467/18723 | 2.76e-06 | 9.42e-05 | 63 |
| GO:004211021 | Breast | DCIS | T cell activation | 65/1390 | 487/18723 | 2.78e-06 | 9.42e-05 | 65 |
| GO:006032621 | Breast | DCIS | cell chemotaxis | 46/1390 | 310/18723 | 5.05e-06 | 1.48e-04 | 46 |
| GO:003059321 | Breast | DCIS | neutrophil chemotaxis | 22/1390 | 103/18723 | 5.36e-06 | 1.56e-04 | 22 |
| GO:001988214 | Breast | DCIS | antigen processing and presentation | 22/1390 | 106/18723 | 8.76e-06 | 2.38e-04 | 22 |
| GO:009753021 | Breast | DCIS | granulocyte migration | 27/1390 | 148/18723 | 1.13e-05 | 2.92e-04 | 27 |
| GO:199026621 | Breast | DCIS | neutrophil migration | 23/1390 | 122/18723 | 2.87e-05 | 6.42e-04 | 23 |
| GO:005087823 | Breast | DCIS | regulation of body fluid levels | 50/1390 | 379/18723 | 5.17e-05 | 1.06e-03 | 50 |
| GO:004206024 | Breast | DCIS | wound healing | 54/1390 | 422/18723 | 6.09e-05 | 1.22e-03 | 54 |
| GO:000247422 | Breast | DCIS | antigen processing and presentation of peptide antigen via MHC class I | 9/1390 | 28/18723 | 1.26e-04 | 2.18e-03 | 9 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0407110 | Cervix | CC | Sphingolipid signaling pathway | 35/1267 | 121/8465 | 5.70e-05 | 3.93e-04 | 2.32e-04 | 35 |
| hsa04664 | Cervix | CC | Fc epsilon RI signaling pathway | 22/1267 | 68/8465 | 2.35e-04 | 1.31e-03 | 7.77e-04 | 22 |
| hsa05152 | Cervix | CC | Tuberculosis | 42/1267 | 180/8465 | 1.78e-03 | 7.21e-03 | 4.26e-03 | 42 |
| hsa053107 | Cervix | CC | Asthma | 11/1267 | 31/8465 | 3.82e-03 | 1.36e-02 | 8.03e-03 | 11 |
| hsa046254 | Cervix | CC | C-type lectin receptor signaling pathway | 25/1267 | 104/8465 | 9.52e-03 | 2.94e-02 | 1.74e-02 | 25 |
| hsa046115 | Cervix | CC | Platelet activation | 28/1267 | 124/8465 | 1.50e-02 | 4.45e-02 | 2.63e-02 | 28 |
| hsa0407113 | Cervix | CC | Sphingolipid signaling pathway | 35/1267 | 121/8465 | 5.70e-05 | 3.93e-04 | 2.32e-04 | 35 |
| hsa046641 | Cervix | CC | Fc epsilon RI signaling pathway | 22/1267 | 68/8465 | 2.35e-04 | 1.31e-03 | 7.77e-04 | 22 |
| hsa051521 | Cervix | CC | Tuberculosis | 42/1267 | 180/8465 | 1.78e-03 | 7.21e-03 | 4.26e-03 | 42 |
| hsa0531012 | Cervix | CC | Asthma | 11/1267 | 31/8465 | 3.82e-03 | 1.36e-02 | 8.03e-03 | 11 |
| hsa0462511 | Cervix | CC | C-type lectin receptor signaling pathway | 25/1267 | 104/8465 | 9.52e-03 | 2.94e-02 | 1.74e-02 | 25 |
| hsa0461113 | Cervix | CC | Platelet activation | 28/1267 | 124/8465 | 1.50e-02 | 4.45e-02 | 2.63e-02 | 28 |
| hsa0531021 | Cervix | HSIL_HPV | Asthma | 11/459 | 31/8465 | 3.33e-07 | 8.88e-06 | 7.18e-06 | 11 |
| hsa051522 | Cervix | HSIL_HPV | Tuberculosis | 19/459 | 180/8465 | 3.99e-03 | 2.39e-02 | 1.93e-02 | 19 |
| hsa0531031 | Cervix | HSIL_HPV | Asthma | 11/459 | 31/8465 | 3.33e-07 | 8.88e-06 | 7.18e-06 | 11 |
| hsa051523 | Cervix | HSIL_HPV | Tuberculosis | 19/459 | 180/8465 | 3.99e-03 | 2.39e-02 | 1.93e-02 | 19 |
| hsa040718 | Liver | HCC | Sphingolipid signaling pathway | 72/4020 | 121/8465 | 5.01e-03 | 1.47e-02 | 8.18e-03 | 72 |
| hsa046112 | Liver | HCC | Platelet activation | 71/4020 | 124/8465 | 1.77e-02 | 4.15e-02 | 2.31e-02 | 71 |
| hsa0407111 | Liver | HCC | Sphingolipid signaling pathway | 72/4020 | 121/8465 | 5.01e-03 | 1.47e-02 | 8.18e-03 | 72 |
| hsa0461111 | Liver | HCC | Platelet activation | 71/4020 | 124/8465 | 1.77e-02 | 4.15e-02 | 2.31e-02 | 71 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FCER1G | SNV | Missense_Mutation | c.107N>A | p.Gly36Glu | p.G36E | P30273 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EK-A2PM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| FCER1G | SNV | Missense_Mutation | c.115N>A | p.Leu39Ile | p.L39I | P30273 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-AP-A0LG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FCER1G | SNV | Missense_Mutation | rs780351889 | c.246N>T | p.Glu82Asp | p.E82D | P30273 | protein_coding | tolerated(0.16) | benign(0.222) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FCER1G | SNV | Missense_Mutation | c.134G>A | p.Arg45Gln | p.R45Q | P30273 | protein_coding | deleterious(0.01) | probably_damaging(0.992) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| FCER1G | SNV | Missense_Mutation | c.121N>A | p.Leu41Ile | p.L41I | P30273 | protein_coding | tolerated(0.5) | probably_damaging(0.925) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FCER1G | SNV | Missense_Mutation | novel | c.109N>C | p.Ile37Leu | p.I37L | P30273 | protein_coding | tolerated(0.08) | benign(0.006) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FCER1G | SNV | Missense_Mutation | novel | c.52G>A | p.Ala18Thr | p.A18T | P30273 | protein_coding | deleterious(0) | benign(0.159) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
| FCER1G | SNV | Missense_Mutation | rs538957910 | c.65N>A | p.Pro22His | p.P22H | P30273 | protein_coding | deleterious(0.05) | probably_damaging(0.999) | TCGA-56-8504-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 2207 | FCER1G | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | R112 | |||
| 2207 | FCER1G | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | BENZYLPENICILLOYL POLYLYSINE | |||
| 2207 | FCER1G | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | aspirin | ASPIRIN | 18595682,18534082 | |
| 2207 | FCER1G | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | BENZYLPENICILLOYL POLYLYSINE |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |